X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-05-14 | MDGL | Madrigal Pharmaceuticals, Inc. | Craves Fred B | Dir | S - Sale+OE | $212.88 | -22,489 | 489,685 | -4% | -$4,787,404 | |||||
| M | 2024-05-14 | SPRY | Ars Pharmaceuticals, Inc. | Tanimoto Sarina | Chief Medical Officer, 10% | S - Sale | $9.05 | -100,000 | 12,665,600 | -1% | -$905,441 | |||||
| M | 2024-05-14 | SPRY | Ars Pharmaceuticals, Inc. | Lowenthal Richard E | Pres, CEO, 10% | S - Sale | $9.05 | -100,000 | 14,307,793 | -1% | -$905,441 | |||||
| M | 2024-05-14 | AMLX | Amylyx Pharmaceuticals, Inc. | Quimi Daphne | Dir | P - Purchase | $1.89 | +5,000 | 5,000 | New | +$9,436 | |||||
2024-05-15 | AMLX | Amylyx Pharmaceuticals, Inc. | Mazzariello Gina | GC | S - Sale | $1.88 | -10,455 | 151,477 | -6% | -$19,654 | ||||||
| D | 2024-05-14 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale+OE | $25.00 | -1,107 | 394,027 | 0% | -$27,675 | |||||
| D | 2024-05-14 | COLL | Collegium Pharmaceutical, Inc | Bohlin Garen G | Dir | S - Sale+OE | $32.30 | -28,985 | 52,468 | -36% | -$936,311 | |||||
2024-05-03 | TSVT | 2Seventy Bio, Inc. | Snow Jessica | See Remarks | S - Sale | $4.91 | -15 | 56,271 | 0% | -$74 | ||||||
| D | 2024-05-14 | RNA | Avidity Biosciences, Inc. | Maclean Michael F | CFO | S - Sale+OE | $28.28 | -75,000 | 44,093 | -63% | -$2,121,045 | |||||
| DM | 2024-05-14 | IDYA | Ideaya Biosciences, Inc. | Hata Yujiro S | Pres, CEO | S - Sale+OE | $42.27 | -175,000 | 677,887 | -21% | -$7,397,291 | |||||
2024-05-15 | CYRX | Cryoport, Inc. | Berman Richard J | Dir | S - Sale | $13.41 | -8,105 | 100,000 | -7% | -$108,693 | ||||||
2024-05-14 | ANIP | Ani Pharmaceuticals Inc | Lalwani Nikhil | Pres, CEO | S - Sale | $66.10 | -16,669 | 377,505 | -4% | -$1,101,821 | ||||||
2024-05-14 | ZLAB | Zai Lab Ltd | Edmondson Frazor Titus III | GC | S - Sale | $21.33 | -10,000 | 16,408 | -38% | -$213,346 | ||||||
2024-05-14 | TRDA | Entrada Therapeutics, Inc. | Kim Peter S | Dir | P - Purchase | $14.59 | +25,000 | 92,412 | +37% | +$364,673 | ||||||
| D | 2024-05-15 | UTHR | United Therapeutics Corp | Causey Christopher | Dir | S - Sale+OE | $272.90 | -2,000 | 4,185 | -32% | -$545,800 | |||||
| D | 2024-05-15 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $272.69 | -40,160 | 1,578 | -96% | -$10,951,230 | |||||
| DM | 2024-05-14 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $270.35 | -7,200 | 130 | -98% | -$1,946,522 | |||||
2024-05-15 | ETST | Earth Science Tech, Inc. | Tabraue Mario Guillermo | COO | P - Purchase | $0.15 | +10,000 | 12,291,023 | 0% | +$1,500 | ||||||
2024-05-14 | RPHM | Reneo Pharmaceuticals, Inc. | Leonard Braden Michael | 10% | P - Purchase | $1.54 | +414,281 | 3,692,963 | +13% | +$639,578 | ||||||
2024-05-15 | BSPK | Bespoke Extracts, Inc. | Feinsod Michael | CEO, 10% | P - Purchase | $0.15 | +3,000 | 2,136,112 | 0% | +$450 | ||||||
| D | 2024-05-13 | CORT | Corcept Therapeutics Inc | Maduck Sean | See Remarks | S - Sale+OE | $28.00 | -50,000 | 105,222 | -32% | -$1,400,000 | |||||
| M | 2024-05-13 | LGND | Ligand Pharmaceuticals Inc | Korenberg Matthew E | Pres, COO | S - Sale | $84.99 | -17,598 | 86,263 | -17% | -$1,495,740 | |||||
2024-05-14 | CYRX | Cryoport, Inc. | Zecchini Edward J | Chief Digital, Tech Officer | S - Sale | $13.37 | -3,443 | 60,051 | -5% | -$46,042 | ||||||
2024-05-14 | ARDX | Ardelyx, Inc. | Raab Michael | Pres, CEO | S - Sale | $7.99 | -3,000 | 1,333,297 | 0% | -$23,970 | ||||||
| DM | 2024-05-14 | REGN | Regeneron Pharmaceuticals, Inc. | Schleifer Leonard S | Bd. Co-Chair, Pres, CEO | S - Sale+OE | $979.58 | -35,941 | 718,176 | -5% | -$35,207,110 | |||||
| M | 2024-05-13 | GNLX | Genelux Corp | Szalay Aladar | 10% | S - Sale | $3.63 | -35,966 | 3,953,581 | -1% | -$130,377 | |||||
2024-05-14 | VERV | Verve Therapeutics, Inc. | Ashe Andrew D. | See Remarks | P - Purchase | $6.26 | +76,000 | 342,509 | +29% | +$475,760 | ||||||
2024-05-15 | CLSD | Clearside Biomedical, Inc. | Yerxa Benjamin R | Dir | P - Purchase | $1.31 | +7,813 | 17,957 | +77% | +$10,235 | ||||||
| M | 2024-05-13 | EOLS | Evolus, Inc. | Gill David N | Dir | S - Sale | $12.64 | -10,361 | 33,964 | -23% | -$131,010 | |||||
2024-05-13 | EOLS | Evolus, Inc. | Malik Vikram | Dir | S - Sale | $12.93 | -28,000 | 254,014 | -10% | -$362,012 | ||||||
2024-05-13 | NUVL | Nuvalent, Inc. | Shair Matthew | Dir | S - Sale | $65.84 | -37,500 | 1,661,220 | -2% | -$2,468,866 | ||||||
2024-05-14 | LIPO | Lipella Pharmaceuticals Inc. | Kaufman Jonathan H | See remarks below., 10% | P - Purchase | $0.76 | +10,000 | 898,849 | +1% | +$7,590 | ||||||
| D | 2024-05-14 | INSM | Insmed Inc | Wise John Drayton | Chief Commercial Officer | S - Sale+OE | $25.47 | -5,088 | 123,259 | -4% | -$129,591 | |||||
| D | 2024-05-14 | INSM | Insmed Inc | Smith Michael Alexander | GC | S - Sale+OE | $25.40 | -5,093 | 94,579 | -5% | -$129,362 | |||||
| D | 2024-05-14 | INSM | Insmed Inc | Schaeffer Orlov S Nicole | Chief People Strategy Officer | S - Sale+OE | $25.53 | -6,508 | 108,760 | -6% | -$166,149 | |||||
| D | 2024-05-14 | INSM | Insmed Inc | Lewis William | Chair, CEO | S - Sale+OE | $25.52 | -22,198 | 668,549 | -3% | -$566,493 | |||||
| D | 2024-05-14 | INSM | Insmed Inc | Flammer Martina M.D. | Chief Medical Officer | S - Sale+OE | $25.47 | -10,640 | 110,776 | -9% | -$271,001 | |||||
| D | 2024-05-14 | INSM | Insmed Inc | Bonstein Sara | CFO | S - Sale+OE | $25.32 | -11,088 | 117,481 | -9% | -$280,748 | |||||
| D | 2024-05-14 | INSM | Insmed Inc | Adsett Roger | COO | S - Sale+OE | $25.50 | -7,857 | 155,220 | -5% | -$200,354 | |||||
2024-05-14 | ZOM | Zomedica Corp. | Powers Johnny D | Dir | P - Purchase | $0.14 | +50,000 | 2,100,000 | +2% | +$6,981 | ||||||
| D | 2024-05-14 | UTHR | United Therapeutics Corp | Patusky Christopher | Dir | S - Sale+OE | $264.35 | -1,310 | 1,100 | -54% | -$346,299 | |||||
2024-05-13 | ALXO | Alx Oncology Holdings Inc | Randolph Sophia | Chief Medical Officer | S - Sale | $15.94 | -12,000 | 330,349 | -4% | -$191,339 | ||||||
2024-05-13 | GTHX | G1 Therapeutics, Inc. | Umstead John W. V | CFO | S - Sale | $4.79 | -8,151 | 153,245 | -5% | -$39,034 | ||||||
2024-05-13 | GTHX | G1 Therapeutics, Inc. | Murdock Terry L | COO | S - Sale | $4.79 | -8,151 | 95,487 | -8% | -$39,034 | ||||||
2024-05-13 | GTHX | G1 Therapeutics, Inc. | Malik Rajesh | Chief Medical Officer | S - Sale | $4.79 | -8,151 | 161,787 | -5% | -$39,034 | ||||||
2024-05-13 | GTHX | G1 Therapeutics, Inc. | Avagliano Mark | Chief Business Officer | S - Sale | $4.79 | -8,151 | 209,683 | -4% | -$39,034 | ||||||
2024-05-13 | GTHX | G1 Therapeutics, Inc. | Bailey John E. (Jack) Jr. | Pres, CEO | S - Sale | $4.79 | -37,258 | 452,336 | -8% | -$178,421 | ||||||
2024-05-13 | ZLAB | Zai Lab Ltd | Smiley Joshua L | See Remarks | P - Purchase | $21.40 | +3,000 | 31,684 | +10% | +$64,200 | ||||||
2024-05-14 | NVCT | Nuvectis Pharma, Inc. | Bentsur Ron | COB, CEO, 10% | P - Purchase | $6.74 | +1,940 | 3,246,424 | 0% | +$13,076 | ||||||
2024-05-13 | TEVA | Teva Pharmaceutical Industries Ltd | Conway Vikki L | See "Remarks" | S - Sale | $16.74 | -15,219 | 0 | -100% | -$254,807 | ||||||
2024-05-13 | BHVN | Biohaven Ltd. | Bailey Gregory | Dir | P - Purchase | $34.19 | +15,000 | 1,615,071 | +1% | +$512,877 | ||||||
2024-05-14 | ETST | Earth Science Tech, Inc. | Sanchez Yovan Arturo | Dir | P - Purchase | $0.14 | +150,000 | 910,500 | +20% | +$20,250 | ||||||
2024-05-14 | IMMX | Immix Biopharma, Inc. | Morris Gabriel S | CFO | P - Purchase | $2.23 | +4,500 | 332,519 | +1% | +$10,042 | ||||||
2024-05-14 | IMMX | Immix Biopharma, Inc. | Rachman Ilya M | CEO, COB | P - Purchase | $2.25 | +4,300 | 912,000 | 0% | +$9,660 | ||||||
2024-05-10 | IOBT | Io Biotech, Inc. | Novo Holdings A/S | 10% | S - Sale | $1.22 | -658,809 | 4,429,449 | -13% | -$802,495 | ||||||
2024-05-13 | MNKD | Mannkind Corp | Binder Steven B. | EVP Special Projects | S - Sale | $4.31 | -3,618 | 845,967 | 0% | -$15,594 | ||||||
2024-05-13 | MNKD | Mannkind Corp | Thomson David | EVP Genl Counsel, Secretary | S - Sale | $4.31 | -3,047 | 783,446 | 0% | -$13,133 | ||||||
2024-05-10 | EOLS | Evolus, Inc. | Moatazedi David | See Remarks | S - Sale | $12.72 | -16,051 | 673,563 | -2% | -$204,127 | ||||||
2024-05-10 | EOLS | Evolus, Inc. | Avelar Rui | See Remarks | S - Sale | $12.72 | -3,441 | 368,847 | -1% | -$43,761 | ||||||
2024-05-10 | EOLS | Evolus, Inc. | Beaver Sandra | CFO | S - Sale | $12.72 | -2,423 | 151,778 | -2% | -$30,814 | ||||||
2024-05-10 | CRNX | Crinetics Pharmaceuticals, Inc. | Betz Stephen F. | Chief Scientific Officer | S - Sale | $49.43 | -3,000 | 89,643 | -3% | -$148,290 | ||||||
2024-05-10 | DAWN | Day One Biopharmaceuticals, Inc. | Blackman Samuel C. | HEAD OF R, D | S - Sale | $16.37 | -10,000 | 2,164,662 | 0% | -$163,743 | ||||||
| A | 2024-05-01 | ALRN | Aileron Therapeutics, Inc. | University of Texas/Texas Am Investment Management Co | 10% | S - Sale | $4.21 | -20,315 | 1,790,142 | -1% | -$85,473 | |||||
| D | 2024-05-10 | ABT | Abbott Laboratories | Funck, Jr. Robert E. | EVP | S - Sale+OE | $104.57 | -10,097 | 270,606 | -4% | -$1,055,819 | |||||
| D | 2024-05-10 | CERE | Cerevel Therapeutics Holdings, Inc. | Coles N Anthony | Dir | S - Sale+OE | $42.10 | -50,000 | 15,638 | -76% | -$2,105,125 | |||||
| D | 2024-05-10 | TRVI | Trevi Therapeutics, Inc. | Good Jennifer L | Pres, CEO | S - Sale+OE | $2.90 | -4,578 | 213,313 | -2% | -$13,276 | |||||
2024-05-13 | ZOM | Zomedica Corp. | Powers Johnny D | Dir | P - Purchase | $0.14 | +100,000 | 2,050,000 | +5% | +$14,000 | ||||||
2024-05-13 | ZOM | Zomedica Corp. | Blair Anthony K | COO | P - Purchase | $0.14 | +150,000 | 150,000 | New | +$21,000 | ||||||
| DM | 2024-05-10 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $265.49 | -7,200 | 130 | -98% | -$1,911,532 | |||||
2024-05-13 | AKBA | Akebia Therapeutics, Inc. | Hadas Nicole R. | SVP, GC | S - Sale | $1.26 | -12,016 | 651,243 | -2% | -$15,140 | ||||||
2024-05-13 | AKBA | Akebia Therapeutics, Inc. | Dahan Michel | SVP, COO | S - Sale | $1.26 | -34,840 | 672,092 | -5% | -$43,898 | ||||||
2024-05-13 | BHVN | Biohaven Ltd. | Childs John W | Dir | P - Purchase | $35.17 | +28,500 | 6,404,244 | 0% | +$1,002,470 | ||||||
| D | 2024-05-09 | CORT | Corcept Therapeutics Inc | Lyon Joseph Douglas | See Remarks | S - Sale+OE | $26.00 | -7,227 | 7,314 | -50% | -$187,902 | |||||
| D | 2024-05-09 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale+OE | $25.06 | -260 | 394,027 | 0% | -$6,515 | |||||
| D | 2024-05-09 | LGND | Ligand Pharmaceuticals Inc | Reardon Andrew | GC, | S - Sale+OE | $83.04 | -10,000 | 22,205 | -31% | -$830,449 | |||||
2024-05-13 | ANIP | Ani Pharmaceuticals Inc | Cook Meredith | SVP, GC, SEC. | S - Sale | $67.69 | -250 | 59,481 | 0% | -$16,923 | ||||||
2024-05-13 | ZOM | Zomedica Corp. | Heaton Larry C II | CEO | P - Purchase | $0.14 | +100,000 | 300,000 | +50% | +$14,200 | ||||||
2024-05-10 | NKTR | Nektar Therapeutics | Deep Track Capital, LP | 10% | S - Sale | $1.78 | -56,000 | 18,344,000 | 0% | -$99,630 | ||||||
2024-05-09 | MNKTQ | Mallinckrodt Plc | Goldentree Asset Management LP | 10% | P - Purchase | $55.37 | +475,000 | 2,874,035 | +20% | +$26,300,000 | ||||||
| D | 2024-05-09 | RYTM | Rhythm Pharmaceuticals, Inc. | Shulman Joseph | Chief Technical Officer | S - Sale+OE | $38.47 | -3,984 | 30 | -99% | -$153,259 | |||||
| DM | 2024-05-09 | BMRN | Biomarin Pharmaceutical Inc | Bienaime Jean Jacques | Dir | S - Sale+OE | $81.38 | -40,000 | 722,527 | -5% | -$3,255,200 | |||||
2024-05-10 | ETST | Earth Science Tech, Inc. | Sanchez Yovan Arturo | Dir | P - Purchase | $0.10 | +10,500 | 760,500 | +1% | +$1,050 | ||||||
2024-05-10 | NVCT | Nuvectis Pharma, Inc. | Bentsur Ron | COB, CEO, 10% | P - Purchase | $6.40 | +2,000 | 3,244,484 | 0% | +$12,800 | ||||||
2024-05-10 | NVCT | Nuvectis Pharma, Inc. | Poradosu Enrique | Chief Science, Business Off | P - Purchase | $6.29 | +500 | 1,504,319 | 0% | +$3,145 | ||||||
2024-05-10 | NVCT | Nuvectis Pharma, Inc. | Shemesh Shay | Chief Dev., Ops. Officer | P - Purchase | $6.32 | +1,113 | 1,493,068 | 0% | +$7,034 | ||||||
| D | 2024-05-08 | CRNX | Crinetics Pharmaceuticals, Inc. | Struthers Richard Scott | Pres, CEO | S - Sale+OE | $49.40 | -107,448 | 1,159,290 | -8% | -$5,307,931 | |||||
| M | 2024-05-08 | TRDA | Entrada Therapeutics, Inc. | Kim Peter S | Dir | P - Purchase | $14.14 | +4,476 | 67,412 | +7% | +$63,306 | |||||
| DM | 2024-05-08 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $263.67 | -7,200 | 130 | -98% | -$1,898,393 | |||||
| D | 2024-05-09 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Chief Medical Officer | S - Sale+OE | $15.00 | -100 | 66,997 | 0% | -$1,500 | |||||
| D | 2024-05-09 | THRD | Third Harmonic Bio, Inc. | Holles Natalie C. | CEO | S - Sale+OE | $12.18 | -20,222 | 1,218,836 | -2% | -$246,300 | |||||
2024-05-10 | XERS | Xeris Biopharma Holdings, Inc. | Schmid John P. | Dir | P - Purchase | $1.91 | +5,400 | 79,559 | +7% | +$10,314 | ||||||
2024-05-09 | ZNTL | Zentalis Pharmaceuticals, Inc. | Hausman Diana | Chief Medical Officer | S - Sale | $12.62 | -3,356 | 373,876 | -1% | -$42,353 | ||||||
2024-05-07 | SPRY | Ars Pharmaceuticals, Inc. | Tanimoto Sarina | Chief Medical Officer, 10% | S - Sale | $9.34 | -100,000 | 12,765,600 | -1% | -$934,365 | ||||||
2024-05-07 | SPRY | Ars Pharmaceuticals, Inc. | Lowenthal Richard E | Pres, CEO, 10% | S - Sale | $9.34 | -100,000 | 12,765,600 | -1% | -$934,365 | ||||||
2023-08-25 | AKBA | Akebia Therapeutics, Inc. | Burke Steven Keith | SVP, Chief Medical Officer | S - Sale | $1.15 | -27,000 | 668,840 | -4% | -$31,050 | ||||||
| D | 2024-05-08 | APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | S - Sale+OE | $42.35 | -78,907 | 1,115,983 | -7% | -$3,341,848 | |||||
| M | 2024-05-07 | GNLX | Genelux Corp | Szalay Aladar | 10% | S - Sale | $3.78 | -19,944 | 3,989,547 | 0% | -$75,300 | |||||
2024-05-07 | FULC | Fulcrum Therapeutics, Inc. | Tourangeau Greg | Principal Accounting Officer | S - Sale | $7.76 | -236 | 11,571 | -2% | -$1,831 | ||||||
2024-05-07 | ADCT | Adc Therapeutics Sa | Mallik Ameet | CEO | S - Sale | $4.48 | -29,731 | 1,167,348 | -2% | -$133,195 | ||||||
| D | 2024-05-06 | ARDX | Ardelyx, Inc. | Felsch Robert Ora | See Remarks | S - Sale+OE | $8.81 | -207,988 | 95,947 | -68% | -$1,831,503 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |